Anti-HIV immunotoxin - Teva Pharmaceutical Industries
Alternative Names: 3B3Latest Information Update: 27 Aug 2007
At a glance
- Originator IVAX Corporation; National Cancer Institute (USA)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Aug 2007 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 12 Feb 2003 Preclinical trials in HIV infections treatment in USA (unspecified route)